AUSTIN, Texas, May 03, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten registered direct offering priced at-the-market under Nasdaq rules of 4,273,505 shares of its common stock and accompanying warrants to purchase an aggregate of 4,273,505 shares of common stock.

德克萨斯州奥斯汀，2024年5月3日（环球通讯社）--生物制药公司Aileron Therapeutics，Inc.（“Aileron”）（纳斯达克股票代码：ALRN）今天宣布，其先前宣布的承销注册直接发行（根据纳斯达克规则在市场上定价）结束，该公司将发行4273505股普通股，并附带购买总计4273505股普通股的认股权证。

Each share of common stock and accompanying warrant were sold together at a combined public offering price of $4.68. The aggregate gross proceeds of the offering were approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses payable by Aileron, and excluding any proceeds that may be received from exercise of the warrants.

每股普通股和附带的认股权证以4.68美元的合并公开发行价格一起出售。在扣除承销折扣和佣金以及副翼应付的其他发售费用（不包括行使认股权证可能获得的任何收益）之前，此次发售的总收益约为2000万美元。

The accompanying warrants have an exercise price of $4.68 per share, are exercisable immediately and expire three years from the date of issuance. Aileron may call the warrants for cancellation during the ten trading day period after the date that is thirty (30) days following the public announcement by Aileron of the top-line results from the Phase 1b clinical trial of LTI-03 in patients with idiopathic pulmonary fibrosis, which announcement includes a statement that there were no drug-related adverse events that resulted in a discontinuation of the trial; provided that Aileron may only deliver such call notice if the volume-weighted average price of its shares of common stock exceeds the exercise price of the warrants on the trading day immediately prior to the date it delivers the call notice.

随附认股权证的行权价格为每股4.68美元，可立即行权，自发行之日起三年内到期。在副翼公布LTI-03特发性肺纤维化患者1b期临床试验的顶级结果后的三十（30）天内，副翼可以在十个交易日内取消认股权证，该公告包括一项声明，即没有导致试验中断的药物相关不良事件；前提是，如果副翼普通股的成交量加权平均价格超过其发出认购通知之日前一交易日权证的行权价格，则副翼只能发出此类认购通知。

Any warrant subject to such call for which a notice of exercise is not rec.

未收到行权通知的受此类催缴的任何认股权证。